Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?

Zhang, Q; Wang, QQ; Wang, XC; Li, J; Shen, L; Peng, Z

Peng, Z (corresponding author), Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol,Minist Educ Beijing, Beijing 100142, Peoples R China.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020; 35 (2): 295

Abstract

Purpose Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking. Here, we......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索